Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection | Active Comparator | we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient. |
|
| Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection | Active Comparator | we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient. |
|
| Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection | Active Comparator | we assess the efficacy of proton pump inhibitors (PPI) based dual therapy for eradication of Helicobacter Pylori infection in naive patient. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection | Drug | we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient. |
| Measure | Description | Time Frame |
|---|---|---|
| efficacy medical treatment for eradication of Helicobacter Pylori infection in naive patient. | stool antigen for H. Pylori | 4 weeks after successful medical treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrew K Wadea, Resident | Contact | 01211498813 | andrewkameel511@gmail.com | |
| Hamdy S Mohammed, Professor | Contact | 01111101934 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sohag University Hospital | Recruiting | Sohag | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27707777 | Background | Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5. | |
| 28071659 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection | Drug | we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient. |
|
| Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection | Drug | we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient. |
|
| Background |
| Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10. |
| 33577874 | Background | Argueta EA, Alsamman MA, Moss SF, D'Agata EMC. Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology. 2021 May;160(6):2181-2183.e1. doi: 10.1053/j.gastro.2021.02.014. Epub 2021 Feb 9. No abstract available. |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 9, 2026 |